Real World One-Year Outcomes of Treatment Intensive Neovascular Age Related Macular Degeneration switched to Faricimab

黄斑变性 医学 眼科 验光服务
作者
Sing Yue Sim,Evangelia Chalkiadaki,Georgios Koutsocheras,Luke Nicholson,Sobha Sivaprasad,Praveen J. Patel,Senthil Selvam,Bishwanath Pal,Pearse A. Keane,B. Bhatia,Robin Hamilton
出处
期刊:Ophthalmology Retina [Elsevier]
标识
DOI:10.1016/j.oret.2024.07.020
摘要

To report 1-year anatomic and functional real-world outcomes of patients with treatment-intensive neovascular age-related macular degeneration (nAMD) switched to faricimab. Retrospective multicenter cohort study. Consecutive nAMD patients on 4-weekly treatment interval with either ranibizumab or aflibercept 2 mg in the last 3 visits within a treat-and-extend protocol (high treatment burden) before switch to faricimab at Moorfields Eye Hospital between September 5, 2022 and December 5, 2022. Patients with nAMD switched to faricimab were identified from electronic medical records and those who met criteria of high treatment burden were included. Data collected included preswitch and postswitch visual acuity (VA), treatment intervals, baseline macular morphology, central subfield thickness (CST), macular fluid status, and adverse events. Visual acuity, CST, presence of intraretinal fluid, subretinal fluid, and injection intervals over 1 year after switch to faricimab. A total of 130 of 286 (45.5%) eyes met inclusion criteria of being switched due to high treatment burden and 117 were included in analysis. Before switch, these eyes received mean total number of injections of 33.4 ± 19.6 over a mean of 51.3 ± 34.9 months. Mean number of injections in 12 months preceding switch was 10.1 ± 1.6 and mean interval of the preceding 3 injections was 4.2 ± 0.3 weeks. Mean VA, CST, and percentage of patients with dry macula before switch were 66.0 ± 11.9 ETDRS letters, 259.6 ± 76.0 μm and 18.3% respectively. After switch, there was no statistical difference in mean VA throughout follow-up period. Mean CST statistically significantly reduced after the third faricimab injection and at 12 months by 20.0 μm (P = 0.035) and 22.1 μm (P = 0.041) respectively. Mean treatment intervals increased to 6.9 ± 2.3 weeks (P < 0.005) at 12 months with 42.9% and 11.4% of patients being on ≥8-weekly and ≥12-weekly treatment intervals, respectively. At 12 months, nAMD patients with previous record of high treatment burden when switched to faricimab maintained VAs and improved anatomic outcomes on extended treatment intervals. Physician bias is inherent in these types of observational studies so a prospective, randomized, controlled trial is recommended to validate these findings. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CIXI完成签到,获得积分10
1秒前
欢喜的小海豚应助东阳采纳,获得10
2秒前
2秒前
侠医2012完成签到,获得积分10
2秒前
4秒前
聪明的泡面完成签到 ,获得积分10
5秒前
拼搏的宇发布了新的文献求助10
6秒前
悦耳的乐松完成签到,获得积分10
6秒前
理想三寻完成签到,获得积分10
7秒前
盐好甜发布了新的文献求助10
8秒前
8秒前
徐叽钰应助白华苍松采纳,获得20
9秒前
欢喜的小海豚应助Luis采纳,获得10
12秒前
lf完成签到,获得积分10
14秒前
拼搏的宇完成签到,获得积分10
14秒前
桔梗完成签到,获得积分10
15秒前
16秒前
小蘑菇应助Why采纳,获得10
16秒前
16秒前
赘婿应助CY采纳,获得10
16秒前
17秒前
zxy完成签到 ,获得积分10
18秒前
18秒前
雨前知了完成签到,获得积分10
19秒前
19秒前
容布丁发布了新的文献求助10
21秒前
可爱的函函应助han采纳,获得10
22秒前
科研通AI2S应助赖账的坦克采纳,获得10
22秒前
161319141完成签到 ,获得积分10
22秒前
桔梗发布了新的文献求助10
22秒前
Star发布了新的文献求助30
23秒前
25秒前
金轩完成签到 ,获得积分10
25秒前
不爱干饭关注了科研通微信公众号
25秒前
27秒前
xx发布了新的文献求助10
28秒前
认真的傲柏完成签到,获得积分10
29秒前
32秒前
33秒前
han完成签到,获得积分10
33秒前
高分求助中
The Oxford Handbook of Social Cognition (Second Edition, 2024) 1050
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Chen Hansheng: China’s Last Romantic Revolutionary 500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3140593
求助须知:如何正确求助?哪些是违规求助? 2791382
关于积分的说明 7798857
捐赠科研通 2447772
什么是DOI,文献DOI怎么找? 1302046
科研通“疑难数据库(出版商)”最低求助积分说明 626434
版权声明 601194